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See the journal website for contents This special issue is recommended for researchers, pathologists, surgeons, physicians and oncologists in the fi eld of gastroenterology, who are interested in the current topics and future perspectives of molecular pathology, tissue engineering, surgery and chemotherapy of gastric cancer. 
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Anaphylaxis is the most dramatic and potentially life-threatening manifestation of an immediate-type hypersensitivity reaction. Although known for over 100 years, it still poses many unresolved questions, and its practical management and acute treatment are often more empiric in nature than evidence-based.
In this book a multidisciplinary group of experts review the state of the art in the pathophysiology, epidemiology, diagnosis and clinical symptomatology of anaphylaxis. Its etiology with regard to diff erent elicitors such as insect venoms, radiocontrast media, analgesics, general and local anesthetics is examined in detail. Finally, treatment modalities for anaphylaxis are discussed both for acute reactions and as general management recommendations for patients at risk. Providing thorough and up-to-date coverage of this frequently underestimated problem, this book is of interest not only to allergologists and immunologists, but also to all physicians and aff ected patients. 
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This special issue is devoted to the changing role of pathology in the context of cancer and its treatment with new drugs such as inhibitors of tyrosine kinases, small molecules and antibodies, as well as combination therapies. The analysis of tissues under combined therapy will be a challenge as diff erent changes will intermingle. A further challenge will be the analysis of follow-up biopsies of the same tumor or of secondary tumors following treatment. In future, pathologists are therefore likely to assume a much more active role in the management of cancer, moving from the position of an observer and describer to that of someone who can suggest modalities of personalized therapy based on the functional properties of the cancer cells under scrutiny. New approaches to treat leukemia, lymphoma, skin, breast, kidney and gastrointestinal cancer are discussed in this issue, which is recommended reading to anyone interested in the pathology of cancers under new treatment options. Digestion concentrates on clinical research reports: in addition to editorials and reviews, the journal features sections on Stomach/Esophagus, Bowel, NeuroGastroenterology, Liver/Bile, Pancreas, Metabolism/Nutrition and Gastrointestinal Oncology. Papers cover physiology in humans, metabolic studies and clinical work on the etiology, diagnosis, and therapy of human diseases. It is thus especially cut out for gastroenterologists employed in hospitals and outpatient units. Moreover, the journal's coverage of studies on the metabolism and effects of therapeutic drugs carries considerable value for clinicians and investigators beyond the immediate field of gastroenterology.
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